Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders

Weihong Kuang,1,* Liantian Tian,2,* Lili Yue,1 Jin Li1 1Department of Psychiatry and Mental Health Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Occupational Respiratory Disease Research Center, No 4 West China Hospital/West China School of Public...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kuang W, Tian L, Yue L, Li J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Major Depressive Disorder Jiuweizhenxin-keli Escitalopram MMN P50 Neuroplasticity Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/1193a496130b4cdd93d6524a39a124a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1193a496130b4cdd93d6524a39a124a1
record_format	dspace
spelling	oai:doaj.org-article:1193a496130b4cdd93d6524a39a124a12021-12-02T01:00:44ZEffects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders1178-2021https://doaj.org/article/1193a496130b4cdd93d6524a39a124a12016-08-01T00:00:00Zhttps://www.dovepress.com/effects-of-escitalopram-with-a-chinese-traditional-compound-jiuweizhen-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Weihong Kuang,1,* Liantian Tian,2,* Lili Yue,1 Jin Li1 1Department of Psychiatry and Mental Health Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Occupational Respiratory Disease Research Center, No 4 West China Hospital/West China School of Public Health, Sichuan University, Chengdu, People’s Republic of China *These authors contributed equally to this work Objective: The objective of this study was to investigate the therapeutic effects of escitalopram in conjunction with Jiuweizhenxin-keli on neuroelectrophysiology in patients with major depressive disorders (MDD).Patients and methods: Patients with depressive episode of MDD according to the criteria of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were randomly assigned to Esc group (30 patients) receiving escitalopram treatment and JK group (30 patients) treated with a combination of escitalopram and Jiuweizhenxin-keli. The healthy control (HC) group (30 persons with normal health condition) served as control. All groups were subject to examination of 24-item Hamilton Depression Rating Scale and Hamilton Anxiety Scale, mismatch negativity (MMN), and sensory gating potential P50 (SG-P50) of event-related potentials. Data were collected at three different time points: baseline (before treatment) and week 2 and week 6 post treatment.Results: At baseline, all electrophysiological parameters of patients with MDD were significantly higher than those of HCs. After treatment, in the Esc group, MMN latency, S2-P50 amplitude, and S2-P50/S1-P50 amplitude ratio decreased; however, the decrements were not statistically significant compared to either baseline or the HC group. Also, no significant changes were observed in the percentage of individuals whose S2-P50/S1-P50 ≥0.5 in the Esc group. On the other hand, in the JK group after a 6-week treatment, MMN latency (206.35±32.14 ms) was significantly shorter than that of the Esc group (219.57±36.51 ms), S2-P50 amplitude (7.27±4.85 µV) reduced significantly compared with the baseline level (10.21±4.10 µV), the percentage of individuals whose S2-P50/S1-P50 ≥0.5 in the JK group greatly decreased and this was not significantly different compared to that of the HC group (P≥0.05).Conclusion: Neuroplasticity of patients with MDD is apparently disturbed, characterized by aberrant MMN latency and SG-P50-related event-related potential parameters. A combination of escitalopram and Jiuweizhenxin-keli treatment can markedly restore these neuroelectrophysiological features, and thus, could be a novel therapeutic solution for improving the impaired neuroplasticity of MDD patients. Keywords: major depressive disorder, Jiuweizhenxin-keli, escitalopram, MMN, P50, neuroplasticityKuang WTian LYue LLi JDove Medical PressarticleMajor Depressive DisorderJiuweizhenxin-keliEscitalopramMMNP50NeuroplasticityNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2016, Iss Issue 1, Pp 1935-1941 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Major Depressive Disorder Jiuweizhenxin-keli Escitalopram MMN P50 Neuroplasticity Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Major Depressive Disorder Jiuweizhenxin-keli Escitalopram MMN P50 Neuroplasticity Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Kuang W Tian L Yue L Li J Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders
description	Weihong Kuang,1,* Liantian Tian,2,* Lili Yue,1 Jin Li1 1Department of Psychiatry and Mental Health Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Occupational Respiratory Disease Research Center, No 4 West China Hospital/West China School of Public Health, Sichuan University, Chengdu, People’s Republic of China *These authors contributed equally to this work Objective: The objective of this study was to investigate the therapeutic effects of escitalopram in conjunction with Jiuweizhenxin-keli on neuroelectrophysiology in patients with major depressive disorders (MDD).Patients and methods: Patients with depressive episode of MDD according to the criteria of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were randomly assigned to Esc group (30 patients) receiving escitalopram treatment and JK group (30 patients) treated with a combination of escitalopram and Jiuweizhenxin-keli. The healthy control (HC) group (30 persons with normal health condition) served as control. All groups were subject to examination of 24-item Hamilton Depression Rating Scale and Hamilton Anxiety Scale, mismatch negativity (MMN), and sensory gating potential P50 (SG-P50) of event-related potentials. Data were collected at three different time points: baseline (before treatment) and week 2 and week 6 post treatment.Results: At baseline, all electrophysiological parameters of patients with MDD were significantly higher than those of HCs. After treatment, in the Esc group, MMN latency, S2-P50 amplitude, and S2-P50/S1-P50 amplitude ratio decreased; however, the decrements were not statistically significant compared to either baseline or the HC group. Also, no significant changes were observed in the percentage of individuals whose S2-P50/S1-P50 ≥0.5 in the Esc group. On the other hand, in the JK group after a 6-week treatment, MMN latency (206.35±32.14 ms) was significantly shorter than that of the Esc group (219.57±36.51 ms), S2-P50 amplitude (7.27±4.85 µV) reduced significantly compared with the baseline level (10.21±4.10 µV), the percentage of individuals whose S2-P50/S1-P50 ≥0.5 in the JK group greatly decreased and this was not significantly different compared to that of the HC group (P≥0.05).Conclusion: Neuroplasticity of patients with MDD is apparently disturbed, characterized by aberrant MMN latency and SG-P50-related event-related potential parameters. A combination of escitalopram and Jiuweizhenxin-keli treatment can markedly restore these neuroelectrophysiological features, and thus, could be a novel therapeutic solution for improving the impaired neuroplasticity of MDD patients. Keywords: major depressive disorder, Jiuweizhenxin-keli, escitalopram, MMN, P50, neuroplasticity
format	article
author	Kuang W Tian L Yue L Li J
author_facet	Kuang W Tian L Yue L Li J
author_sort	Kuang W
title	Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders
title_short	Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders
title_full	Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders
title_fullStr	Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders
title_full_unstemmed	Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders
title_sort	effects of escitalopram with a chinese traditional compound jiuweizhenxin-keli on mismatch negativity and p50 in patients with major depressive disorders
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/1193a496130b4cdd93d6524a39a124a1
work_keys_str_mv	AT kuangw effectsofescitalopramwithachinesetraditionalcompoundjiuweizhenxinkelionmismatchnegativityandp50inpatientswithmajordepressivedisorders AT tianl effectsofescitalopramwithachinesetraditionalcompoundjiuweizhenxinkelionmismatchnegativityandp50inpatientswithmajordepressivedisorders AT yuel effectsofescitalopramwithachinesetraditionalcompoundjiuweizhenxinkelionmismatchnegativityandp50inpatientswithmajordepressivedisorders AT lij effectsofescitalopramwithachinesetraditionalcompoundjiuweizhenxinkelionmismatchnegativityandp50inpatientswithmajordepressivedisorders
_version_	1718403361199357952

Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders

Ejemplares similares